First-line immunotherapy fails to improve OS outside of trials for older adults with NSCLC

First-line immunotherapy fails to improve OS outside of trials for older adults with NSCLC
Disclosures:
The Doris Duke Charitable Foundation, Health Data Analytics Institute, NCI, Simeon J. Fortin Foundation and Wong Family Foundation supported the study. Kehl reports personal fees from Aetion, IBM Corporation and Roche outside the submitted work. Please see the study for all other authors’ relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Subscribe
ADDED TO EMAIL ALERTS
You've successfully added to your alerts. You will receive an email when new content is published.

Related Keywords

Brookline ,Massachusetts ,United States ,Boston ,Dana Farber Cancer Institute ,Kennethl Kehl , ,Health Data Analytics Institute ,Harvard Medical School ,Risk Stratification Index ,புரூக்லைன் ,மாசசூசெட்ஸ் ,ஒன்றுபட்டது மாநிலங்களில் ,போஸ்டன் ,டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் ,ஆரோக்கியம் தகவல்கள் பகுப்பாய்வு நிறுவனம் ,ஹார்வர்ட் மருத்துவ பள்ளி ,